<?xml version="1.0" encoding="UTF-8"?>
<p>Large antibody libraries are crucial in response to rapidly emerging pathogens. Using eight large phage-displayed VH, scFv, and Fab libraries and panning against the RBD of the SARS-CoV-2, Li et al. identified an exceptional potent (
 <italic>K</italic>
 <sub>d</sub> to RBD of 160 pM as judged by biolayer interferometry) mAb IgG1 ab1 that competes with ACE2 in vitro and protected transgenic mice expressing hACE2 from high-titer intranasal SARS-CoV-2 challenge.
 <sup>
  <xref ref-type="bibr" rid="ref53">53</xref>
 </sup> In two different assays using replication-competent SARS-CoV-2 in a microneutralization-based assay, 100% neutralization at &lt;400 nM, and in a luciferase reporter gene assay, an IC
 <sub>50</sub> of 200 nM was reported. Moreover, transgenic mice expressing human ACE2 administrated with 0.3 mg of Ig1 ab1 prior intranasal infection with SARS-CoV-2 did not show any detectable replication-competent virus, demonstrating the preventive effect of IgG1 ab1.
 <sup>
  <xref ref-type="bibr" rid="ref53">53</xref>
 </sup>
</p>
